Methotrexate in the therapy of juvenile idiopathic arthritis;Methotrexat bei der Therapie der juvenilen idiopathischen Arthritis

Zeitschrift fur Rheumatologie

Volumn 69, Issue 6, 2010, Pages 496-504

  Holzinger, D ^a   Frosch, M ^a   Foll D ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Juvenile idiopathic arthritis; Methotrexate; Side effects; Therapy

Indexed keywords

AMINOTRANSFERASE; BIOLOGICAL MARKER; ETANERCEPT; FOLIC ACID; METHOTREXATE; PROBENECID; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; CHILD; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; NAUSEA; REVIEW; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; VOMITING;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLIC ACID; HUMANS; METHOTREXATE; TREATMENT OUTCOME;

EID: 77956339258     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-010-0633-1     Document Type: Review

References (36)

1. Albers HM, Wessels JA, Van Der Straaten RJ et al (2009) Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 61:46-51
2. Balis FM, Savitch JL, Bleyer WA (1983) Pharmacokinetics of oral methotrexate in children. Cancer Res 43:2342-2345
3. Bartoli M, Taro M, Magni-Manzoni S et al (2008) The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 67:370-374
4. Brik R, Berkowitz D, Berant M (1998) Duration of methotrexate treatment until partial and total remission of refractory juvenile rheumatoid arthritis. Ann Rheum Dis 57:174-175
5. Buckley LM, Bullaboy CA, Leichtman L et al (1997) Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 40:971-973
6. Cassidy JT (1999) Medical management of children with juvenile rheumatoid arthritis. Drugs 58:831-850
7. Chedeville G, Quartier P, Miranda M et al (2005) Improvements in growth parameters in children with juvenile idiopathic arthritis associated with the effect of methotrexate on disease activity. Joint Bone Spine 72:392-396
8. Cleary AG, Mcdowell H, Sills JA (2002) Polyarticular juvenile idiopathic arthritis treated with methotrexate complicated by the development of non-Hodgkins lymphoma. Arch Dis Child 86:47-49
9. Cutolo M, Sulli A, Pizzorni C et al (2001) Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 60:729-735
10. Foell D, Wittkowski H, Hammerschmidt I et al (2004) Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 50:1286-1295
11. Giannini EH, Brewer EJ, Kuzmina N et al (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The pediatric rheumatology collaborative study group and the cooperative childrens study group. N Engl J Med 326:1043-1049
12. Gottlieb BS, Keenan GF, Lu T et al (1997) Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics 100:994-997
13. Guellac N, Niehues T (2008) Interdisciplinary and evidence-based treatment guideline for juvenile idiopathic arthritis. Klin Padiatr 220:392-402
14. Hashkes PJ, Balistreri WF, Bove KE et al (1997) The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum 40:2226-2234
15. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E et al (2007) Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis 66:1384-1387
16. Horneff G, De Bock F, Foeldvari I et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA registry. Ann Rheum Dis 68:519-525
17. Hunt PG, Rose CD, Mcilvain-Simpson G et al (1997) The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol 24:2230-2232
18. Jundt JW, Browne BA, Fiocco GP et al (1993) A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 20:1845-1849
19. Katchamart W, Trudeau J, Phumethum V et al (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 68:1105-1112
20. Kremer JM, Zablocki R, Dervieux T (2009) Switching from oral to parenteral methotrexate administration produces clinical improvements through selective accumulation of long-chains methotrexate polyglutamates. Arthritis Rheum 60:400
21. Krugmann J, Sailer-Hock M, Muller T et al (2000) Epstein-Barr virus-associated Hodgkins lymphoma and legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A. Hum Pathol 31:253-255
22. Londino AV Jr, Blatt J, Knisely AS (1998) Hodgkins disease in a patient with juvenile rheumatoid arthritis taking weekly low dose methotrexate. J Rheumatol 25:1245-1246
23. Masi L, Ricci L, Zulian F et al (2009) Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis. J Rheumatol 36:2308-2313
24. Niehues T, Horneff G, Michels H et al (2004) Evidence-based use of methotrexate in children with rheumatic disorders. Consensus statement of the Working Group for Children and Adolescents with Rheumatic Diseases in Germany (AGKJR) and the Working Group Pediatric Rheumatology Austria. Z Rheumatol 63:147-158
25. Ortiz Z, Shea B, Suarez-Almazor ME et al (1998) The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 25:36-43
26. Ravelli A, Martini A (2000) Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol 27:1830-1833
27. Ravelli A, Migliavacca D, Viola S et al (1999) Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 17:625-627
28. Ravelli A, Viola S, Migliavacca D et al (1999) The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 135:316-320
29. Ravelli A, Viola S, Ramenghi B et al (1995) Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. J Rheumatol 22:1574-1576
30. Ruperto N, Lovell DJ, Cuttica R et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096-3106
31. Ruperto N, Lovell DJ, Quartier P et al (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62:1792-1802
32. Ruperto N, Lovell DJ, Quartier P et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372:383-391
33. Ruperto N, Murray KJ, Gerloni V et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50:2191-2201
34. Seitz M, Zwicker M, Loetscher P (1998) Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum 41:2032-2038
35. Singsen BH, Goldbach-Mansky R (1997) Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. Rheum Dis Clin North Am 23:811-840
36. Van Der Meer A, Wulffraat NM, Prakken BJ et al (2007) Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 25:480-485